Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC591 for Prevention of Oxaliplatin-Induced Peripheral Neuropathy
NCT06722950Phase 2Not yet recruiting
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- HM (Herbal Medicine)
01
Overview
A Phase 2 trial of AC591, sponsored by Shandong New Time Pharmaceutical. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
AC591
Beyond the preview
Go deeper on NCT06722950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06722950.